BC Week In Review | Feb 1, 2016
Clinical News

IX-01: Phase IIa data

The double-blind, U.S. and Australian Phase IIa PEPIX trial in 88 patients with severe lifelong premature ejaculation showed that oral IX-01 given 1-6 hours prior to sexual activity significantly improved IELT by >3.5 fold vs....
BioCentury | Sep 9, 2013
Emerging Company Profile

Ixchelsis: Lasting longer

Ixchelsis Ltd. 's oxytocin receptor antagonist could help treat premature ejaculation more safely than antidepressant SSRIs, which are prescribed off label for the condition. Premature ejaculation is one of the most common male sexual dysfunctions...
BC Week In Review | Aug 12, 2013
Company News

Ixchelsis, Eli Lilly, Pfizer deal

Ixchelsis said in July it acquired rights to IX-01 from Pfizer in exchange for an undisclosed equity stake. The pharma also is eligible for undisclosed milestones and royalties. The oxytocin receptor (OXTR) antagonist is in...
Items per page:
1 - 3 of 3